SLC5A2 and diabetes mellitus: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors were developed for their effects on blood glucose, and large-scale trials mandated by the US FDA were initiated to assess their cardiovascular safety in populations with type 2 diabetes mellitus (DM) at high atherosclerotic cardiovascular (ASCVD) risk [1].